Immune checkpoint inhibitor therapy in advanced cervical cancer: Deepened response with prolonged treatment and repeat response to re-initiation of therapy

Immune checkpoint inhibitors (ICI) were approved in June 2018 for second line treatment of metastatic cervical cancer after progression on platinum-based chemotherapy. A cohort of 10 patients who received single agent ICI as second line treatment was examined, with an initial analysis published in J...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Jennifer, Xu, Yiquing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368812/
https://www.ncbi.nlm.nih.gov/pubmed/37502442
http://dx.doi.org/10.1016/j.gore.2023.101244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368812/
https://www.ncbi.nlm.nih.gov/pubmed/37502442
http://dx.doi.org/10.1016/j.gore.2023.101244

Ejemplares similares